- Home
- ZURA vs PRQR Comparison
ZURA vs PRQR Comparison
Compare ZURA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | PRQR |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZURA | PRQR |
|---|---|---|
| Price | $4.01 | $2.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $11.38 | $8.14 |
| AVG Volume (30 Days) | 359.5K | ★ 558.5K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.97 | $1.07 |
| 52 Week High | $4.68 | $3.46 |
Technical Indicators
Market Signals| Indicator | ZURA | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 53.75 |
| Support Level | $3.58 | $2.15 |
| Resistance Level | $3.94 | $2.42 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 95.69 | 79.70 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.